A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade
出版年份 2019 全文链接
标题
A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade
作者
关键词
-
出版物
ADVANCED MATERIALS
Volume -, Issue -, Pages 1806957
出版商
Wiley
发表日期
2019-03-12
DOI
10.1002/adma.201806957
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Core–Shell Microneedle Gel for Self-Regulated Insulin Delivery
- (2018) Jinqiang Wang et al. ACS Nano
- In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
- (2018) Chao Wang et al. Science Translational Medicine
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment
- (2018) Qian Chen et al. Nature Nanotechnology
- Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
- (2018) Huitong Ruan et al. Advanced Healthcare Materials
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Control of muscle formation by the fusogenic micropeptide myomixer
- (2017) Pengpeng Bi et al. SCIENCE
- DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer
- (2016) Krista P. Terracina et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- Azacitidine in AML: a treatment option?
- (2015) G. Huls BLOOD
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
- (2015) Marie Morfouace et al. JOURNAL OF NEURO-ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
- (2015) L. Wang et al. Cancer Immunology Research
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
- (2013) Felicetto Ferrara HEMATOLOGICAL ONCOLOGY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
- (2012) Amir A. Toor et al. BRITISH JOURNAL OF HAEMATOLOGY
- Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
- (2012) Pierre L. Triozzi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer
- (2011) M. Rao et al. CANCER RESEARCH
- Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression
- (2011) Alfonso Serrano et al. Cancers
- Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression
- (2008) Jennifer A. Wargo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
- (2008) C. B. Yoo et al. Cancer Prevention Research
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now